Renoprotective and anti‐hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen‐2)27 rat

Nephrology Dialysis Transplantation - Tập 16 Số 7 - Trang 1343-1349 - 2001
Jennifer L. Wilkinson‐Berka1, Narelle J. Gibbs, Mark E. Cooper, Sandford L. Skinner, Darren J. Kelly
1Department of Physiology, The University of Melbourne, Australia

Tóm tắt

Từ khóa


Tài liệu tham khảo

Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int1989; 36: 526–536

Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes1997; 46: 1612–1618

Kelly DJ, Wilkinson‐Berka JL, Allen TA, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen‐2)27 rat. Kidney Int1998; 54: 343–352

Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson‐Berka JL. Effects of endothelin or angiotensin receptor blockade on diabetes in the transgenic (mRen‐2)27 rat. Kidney Int2000; 57: 1882–1894

Zatz R, Dunn R, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest1986; 77: 1925–1930

Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res1990; 66: 883–890

Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension1994; 23: 439–449

Liu YH, Yang XP, Sharov VG et al. Effects of angiotensin‐converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest1997; 99: 1926–1935

Nussberger J, Waeber B, Brunner HR. Clinical pharmacology of ACE inhibition. Cardiology1989; 76 [Suppl 2]: 11–22

Chung, O, Kuhl H, Stoll M, Unger T. Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int1998; 54 [Suppl 67]: S95–99

Tallant EA, Diz DI, Ferrario CM. State‐of‐the‐art lecture. Antiproliferative actions of angiotensin (1–7) in vascular smooth muscle. Hypertension1999; 34: 950–957

Okada H, Suzuki H, Kanno Y, Ikenaga H, Saruta T. Renal responses to angiotensin receptor antagonist and angiotensin‐converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol1995; 26: 564–569

Zoja C, Donadelli R, Corna D et al. The renoprotective properties of angiotensin‐converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis1997; 29: 254–264

Ots M, MacKenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol1998; 9: 224–230

Burdmann EA, Takeshi FA, Nast CC et al. Prevention of experimental cyclosporin‐induced interstitial fibrosis by losartan and enalapril. Am J Physiol1995; 269: F491–499

Kohzuki M, Yasujima M, Kanazawa M et al. Antihypertensive and renal‐protective effects of losartan in streptozotocin diabetic rats. J Hypertens1995; 13: 97–103

Menard J, Campbell D, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation1997; 96: 3072–3078

Richer C, Bruneval P, Menard J, Giudicelli JF. Additive effects of enalapril and losartan in (mREN‐2)27 transgenic rats. Hypertension1998; 31: 692–698

Lemmer B, Witte K, Makabe T, Ganten D, Mattes A. Effects of circadian profiles in blood pressure and heart rate of spontaneously and transgenic hypertensive rats. J Cardiovasc Pharmacol1994; 3: 311–314

Arima S, Ito S, Omata K, Takeuchi K, Abe K. High glucose augments angiotensin II action by inhibiting NO synthesis in in vitro microperfused rabbit afferent arterioles. Kidney Int1995; 48: 683–689

Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose‐induced inhibition of mesangial matrix. Diabetes1999; 48: 2066–2073

Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JSD. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int1999; 55: 454–464

Gansevoort RT, de Zeeuw D. The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions. Curr Opin Nephrol Hypertens2000; 9: 57–61

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. Kidney Int2000; 57: 601

Azizi M, Chatellier G, Guyene TT, Murieta‐Geoffroy D, Menard J. Additive effects of combined angiotensin‐converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium‐depleted normotensives. Circulation1995; 92: 825–834

Baruch L, Anand I, Cohen Is, Ziesche S, Judd D, Cohn JN. Augmented short‐ and long‐term hemodynamic and hormonal effects of an angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation1999; 99: 2658–2664

Hebert LA, Falkenhain ME, Nahman Jr NS, Cosio FG, O'Dorisio TM. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol1999; 19: 1–6

Russo D, Pisani A, Balletta MM et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis1999; 33: 851–856

Mogensen CE, Neldman S, Tikkanen I et al. for the CALM study group. Randomised controlled trial of dual blockade of the renin‐angiotensin system in hypertensive, microalbuminuric, non‐insulin dependent diabetes: the candesartan and lisinopril microalbuminuric (CALM) study. BMJ2001; in press